CEO exercised or converted 10K GILD derivative securities | OQRO Insider tradesWhy it stands out
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Dec 10, 2025
- Reporting period
- Not applicable
- Filed with the SEC
- Dec 12, 2025
CEOOption exercise
Context
- Classification
option exercise
Code M — exercise or conversion of a derivative security
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001638643-25-000015
Added to OQROOct 2, 2026, 12:27 PM UTC Data qualityVerified: identifiers matched exactly IssuerGILEAD SCIENCES, INC. Reporting personDaniel Patrick O'day RelationshipDirector, Officer Officer titleChairman & CEO TableNon-derivative (Table I) Transaction dateDec 10, 2025 Acquired / disposedAcquired (A) Shares owned after581,629 Footnotes from the filing
- Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
Around the same time
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Derivative exercise or conversion — not an open-market buy.